Brexit Could Weaken Drug Safety Systems In Both UK And EU, Health Alliance Warns
Executive SummaryLosing access to the EudraVigilance drug safety database after Brexit could lead to delays of up to two months in safety signal detection, and up to five months’ delay in managing new signals, says an alliance of industry, UK National Health Service bodies and medical charities. The alliance also warns that efforts to tackle infectious diseases could be impaired if the UK's role in EU health risk reporting systems is diminished.
You may also be interested in...
One of the many ramifications of the UK’s decision to leave the EU is that it could lose access to the revamped EudraVigilance adverse drug reaction database.
After months of preparations, the European Medicines Agency’s improved pharmacovigilance database has gone live on schedule.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.